

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Cite No: 15

DA

## PATENT ABSTRACTS OF JAPAN

(11)Publication number : 02-161954

(43)Date of publication of application : 21.06.1990

(51)Int.Cl.

A61M 1/34

(21)Application number : 63-316510

(71)Applicant : ASAHI CHEM IND CO LTD

(22)Date of filing : 16.12.1988

(72)Inventor : MANABE SEIICHI  
SATANI MASUO

## (54) PREPARATION OF NONINFECTIOUS MATERIAL CONTAINING ANTIGEN OR ANTIBODY OF VIRUS

## (57)Abstract:

PURPOSE: To treat or prevent a disease by injecting the liquid obtd. by filtering blood plasma or cell culture supernatant contg. virus by porous hollow fibers of a hydrophilic high polymer having a specific structure.

CONSTITUTION: The blood plasma or cell culture supernatant which is positive in the antigen or antibody of virus is prepd. by filtering the same with the porous hollow fibers constituted of a specific pore structure and specific high- polymer base material. The high-polymer base material is regenerated cellulose, polyvinyl alcohol, etc., which are hydrophilic polymers. The pore structure is  $\geq 10\mu\text{m}$  in the film thickness (indicated by d,  $\mu\text{m}$  unit) of the hollow fibers and the average pore size (indicated by  $\mu\text{m}$  unit) by a water filtration rate method satisfies all of  $\leq 1.5$  times the diameter of the virus to be removed,  $\leq 0.2\mu\text{m}$ , and  $\leq (0.004 \times d) \mu\text{m}$  and  $\geq 0.01\mu\text{m}$ . The intra-surface porosity thereof is  $\leq 0.5$  and the pore structure has  $\geq 10$  layers of layer structures in the film thickness direction. The film permeability of the antigen or antibody is thereby made into  $\geq 30\%$  and the permeability of the virus into  $\leq 0.01\%$ . The treatment and prevention and thus enabled.

## LEGAL STATUS

[Date of request for examination]

[Date of sending the examiner's decision of rejection]

[Kind of final disposal of application other than

the examiner's decision of rejection or  
application converted registration]

[Date of final disposal for application]

[Patent number]

[Date of registration]

[Number of appeal against examiner's  
decision of rejection]

[Date of requesting appeal against examiner's  
decision of rejection]

[Date of extinction of right]

Copyright (C); 1998,2003 Japan Patent Office

## XP-002247181

AN - 1990-234808 [31]

AP - JP19880316510 19881216 JP19880316510 19881216; [Previous Publ. J02161954 ]

CPY - ASAH

DC - B04 D16 P34

FS - CPI;GMPI

IC - A61M1/16 ; A61M1/34 ; B01D71/10

MC - B04-B04C1 B04-B04C3 B11-B B12-A02C D05-H07 D05-H09 D05-H11

M1 - [01] M423 M750 M903 N161 Q233 V500 V560 V600 V611; 1327-U 0502-U

- [02] M423 M720 M903 N161 P210 Q233 V600 V614; 1327-U 0502-U

PA - (ASAH ) ASahi CHEM IND CO LTD

PN - JP2161954 A 19900621 DW199031 000pp

- JP2804055B2 B2 19980924 DW199843 A61M1/34 005pp

PR - JP19880316510 19881216

XA - C1990-101528

XIC - A61M-001/16 ; A61M-001/34 ; B01D-071/10

XP - N1990-181986

AB - J02161954 Non-infectious substances contg. viral antigen or antibody are prepd. by (1) sepn. and removal of blood corpuscles or cell components from viral antigen-or antibody-positive blood or suspensions. (2) filtration of the obtd. plasma or cell culture supernatant through a porous hollow fibre comprising hydrophilic polymers of layered structure having a membrane thickness of at least 10 micron a porous dia. is 0.01-0.2 micron m and upto 0.004xd microns by water filtration rate method. The dia. is less than 1.5 times compared with the virus. The void content under the surface is upto 0.5, and it has at least 10 layers in the direction of membrane thickness.

- The virus may be HIV and the plasma for or after filtration may comprise mixed plasma from several human subjects, and the porous hollow fibre used for removal of the virus in the plasma may comprise cellulose regenerated by copper ammonia method. The blood may be HBs antigen- and HBs antibody-positive or HBe antigen- and HBe antibody-positive.

- USE/ADVANTAGE - Hollow fibre has high inhibition ratio against virus, small adsorbability for proteins, and large permeability for plasma proteins and antibodies. Virus-free plasma or suspensions contg. antigen or antibody are obtd. By returning the plasma or suspensions to patients with viral diseases or by the injection to healthy human subjects, the treatment and prevention of these diseases is effected.

(6pp Dwg.No.0/0)

DRL - 1327-U 0502-U

IW - NON INFECT SUBSTANCE CONTAIN VIRUS ANTIGEN ANTIBODY PREPARATION FILTER  
PLASMA CELL CULTURE SUPERNATANT THROUGH POROUS HOLLOW FIBRE

IKW - NON INFECT SUBSTANCE CONTAIN VIRUS ANTIGEN ANTIBODY PREPARATION FILTER  
PLASMA CELL CULTURE SUPERNATANT THROUGH POROUS HOLLOW FIBRE

NC - 001

OPD - 1988-12-16

ORD - 1990-06-21

PAW - (ASAH ) ASahi CHEM IND CO LTD

TL - Non infectious substances contg. viral antigen or antibody prep. by